EC clears new class of anaemia therapy
BMS’ Reblozyl is the first and only erythroid maturation agent approved in the EU
Read More
Tag: luspatercept
Celgene, Acceleron to file MDS therapy in the EU, US
Celgene and Acceleron Pharma are preparing to file their experimental myelodysplastic syndromes (MDS) therapy on both sides of the Atlantic on the back of promising data from a late-stage study.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
